• Avalanche of drugs, scarcely any oversight, II

    About $72 billion in drugs and active ingredients were imported into the U.S. in 2006; the FDA that year spent a mere $12.75 million inspecting foreign production plants; between 3,250 and 6,800 non-U.S. plants export drugs and drug ingredients to the U.S.(the FDA’s two main databases each gives a different figure), and are thus subject to FDA inspection; in the last five years the agency has conducted only 1,445 foreign inspections; main reason: In the face of growing drug and food imports, the Bush administration steadily cut the agency’s budget and resources since 2001

  • Bain's effort to acquire 3Com on verge of collapse

    Bain Capital and a Chinese partner wanted to buy 3Com for $2.2 billion; 3Com’s TippingPoint unit sells security software used by U.S. government agencies, and persistent questions were raised over the national security ramifications of the deal; Bain and Huawei Technologies have now withdrawn their application to CFIUS